论文部分内容阅读
探讨保尔佳在复发性中、高度恶性非霍奇金淋巴瘤再化疗中的使用效果。选取有明确病理诊断且既往用过ＣＨＯＰ方案化疗的复发性非霍奇金淋巴瘤共４８例，随机分为两组，治疗组再次启用ＣＨＯＰ方案化疗，并在化疗前５天开始加用保尔佳针剂３０μｇ肌肉注射，１次／日×２０日，对照组应用ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案，分别评定近期疗效、毒副反应、Ｔ细胞亚群分布状态。治疗组ＣＲ率达３７．５％，对照组为５０．０％，差异无显著性（Ｐ＞０．０５）；两组共有的毒副反应为骨髓抑制、消化道反应及心肌毒性，均能耐受。但治疗组Ⅲ度以上消化道反应低于对照组（Ｐ＜０．０５）；治疗组化疗后Ｔ细胞亚群中ＣＤ＋３、ＣＤ＋４水平明显高于对照组（Ｐ＜０．０１）。保尔佳在复发的ＮＨＬ再化疗中有明显的增敏作用，且能提高机体的细胞免疫功能
To investigate the use of Pulgar in the re-treatment of recurrent, high-grade malignant non-Hodgkin’s lymphoma. A total of 48 recurrent non-Hodgkin’s lymphomas with clear pathological diagnosis and previous CHOP regimen chemotherapy were selected and randomly divided into two groups. The treatment group was re-enabled with CHOP chemotherapy, and began to use Paul 5 days before chemotherapy. 30μg intramuscular injection was injected intramuscularly once a day for 20 days. The ProMACE-CytaBOM regimen was used in the control group to assess the short-term efficacy, toxicities and side effects, and the distribution of T cell subsets. The CR rate of the treatment group was 37.5%, and that of the control group was 50.0%. There was no significant difference (P>0.05). The toxicity common to the two groups was myelosuppression, gastrointestinal reaction, and myocardial toxicity. Tolerance. However, in the treatment group, the digestive tract reaction above III degree was lower than that in the control group (P<0.05). The levels of CD+3 and CD+4 in the T cell subsets after treatment were significantly higher than those in the control group (P<0.01). Bao Jiajia has obvious sensitization effect in relapsed NHL chemotherapy and can improve cellular immune function